Startups
Helio Genomics is an AI-driven healthcare company on a mission to save lives by developing technology that can detect cancer early from a simple blood draw. We are pioneers of a true multi-modal x multi-omics approach to biomarker discovery – optimizing the best combination of biological data to unveil a clear picture of how cancer exists and evolves. In doing so, we challenge cancer by translating those learnings into user-friendly, accessible tools that guide medical decision-making to prevent cancer from progressing.
Helio Genomics is headquartered in the United States with offices in California and Indiana. Helio Genomics is a multinational business with collaborations in both the United States and China, including leading scientists, physicians, research institutions, and business leaders from both countries. Helio Genomics strives to combine the experiences of these innovators and achievers in order to provide the most accurate and safest diagnostic technologies to everyone.
Helio Genomics has CLIA and CAP certified laboratories, 3rd party laboratories, and cGMP facilities all working towards the endeavor of bringing these first-class technologies into the medical community.
Helio Genomics is headquartered in the United States with offices in California and Indiana. Helio Genomics is a multinational business with collaborations in both the United States and China, including leading scientists, physicians, research institutions, and business leaders from both countries. Helio Genomics strives to combine the experiences of these innovators and achievers in order to provide the most accurate and safest diagnostic technologies to everyone.
Helio Genomics has CLIA and CAP certified laboratories, 3rd party laboratories, and cGMP facilities all working towards the endeavor of bringing these first-class technologies into the medical community.
Overview
Location
United States, California, Irvine
Employees
51-200
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 19, 2022 | Dhruvajyoti (Dhruv) Roy, Ph.D. Joins the Editorial Advisory Board of Onco’Zine | The editorial team of Onco’Zine is extremely proud to announce that Dhruvajyoti (Dhruv) Roy, Ph.D., has joined the publication's Editorial Advisory Board. CHANDLER, Ariz. (PRWEB) August 19, 2022 Today, Onco’Zine, an online, science-driven, ... |
| Helio Genomics Appoints Gary Frazier as Chief Growth Officer | Gary Frazier, Chief Growth Officer at Helio Genomics What You Should Know: – Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology for cancer detection, has appointed Gary Frazier as its Chief Growth Officer... | |
| Liver Cancer Awareness – Here’s What You Need to Know in 2023 | Justin Chen Li, CEO of Helio Genomics By the end of 2022, nearly 42,00 new cases of primary liver cancer will be diagnosed in the United States. In fact, liver cancer incidence rates have more than tripled since 1980, marking an increased n... |
Reviews 0
FAQ about Helio Genomics
What has the press written about Helio Genomics?
Parsers VC has collected 4 articles mentioning Helio Genomics, among them “Dhruvajyoti (Dhruv) Roy, Ph.D. Joins the Editorial Advisory Board of Onco’Zine” (Aug 19, 2022) and “Helio Genomics Appoints Gary Frazier as Chief Growth Officer”.
Is Helio Genomics still active?
Yes, Helio Genomics is active; its latest activity on Parsers VC dates from Jan 24, 2024.